Group 1 - The core viewpoint of the announcement is that 联邦制药 expects a net profit of approximately RMB 1.85 billion for the six months ending June 30, 2025, compared to RMB 1.49 billion for the same period in 2024, indicating a significant increase in profitability [1][3] - The increase in net profit is primarily attributed to licensing fee income from Novo Nordisk, amounting to approximately RMB 1.1 billion [3] - However, there was a decline in segment profits from intermediates by approximately RMB 430 million and from active pharmaceutical ingredients by approximately RMB 270 million, which partially offset the profit increase [3] Group 2 - The interim results are not yet finalized and are based on preliminary reviews of management accounts and other available information, which may be subject to adjustments and final confirmation [3] - The company is primarily engaged in the research, development, production, and sales of pharmaceuticals [3]
联邦制药(03933.HK) ： 预期中期净溢利同比上升，约为18.5亿元